Related by context. All words. (Click for frequent words.) 71 refractory chronic lymphocytic 71 BCG refractory carcinoma 68 CYT# potent vascular disrupting 67 HGS ETR1 mapatumumab 67 indolent follicular non 67 sorafenib tablets 67 trastuzumab Herceptin R 67 Kit CD# positive 66 erlotinib Tarceva ® 66 novel VDA molecule 66 irinotecan doxorubicin oxaliplatin paclitaxel 66 stage IIIB 66 Budesonide foam crofelemer 66 stage IIIb IV 65 FUSILEV enhances 65 lenalidomide Revlimid R 65 infliximab monotherapy 65 plus prednisone prednisolone 65 IMPDH inhibitor 65 relapsed MM 65 novel nucleoside analog 65 plus dacarbazine 65 kidney urologic 65 dasatinib Sprycel 65 melphalan prednisone 65 relapsed refractory multiple myeloma 65 Crofelemer budesonide foam 65 recurrent NSCLC 65 Telik logo TELINTRA 65 unresectable tumors 65 dasatinib Sprycel ® 65 R sorafenib tablets 64 metastatic ocular 64 Vicinium TM 64 Improved Progression 64 GRNOPC1 contains 64 gastrointestinal stromal 64 XL# anticancer compounds 64 modified glutathione analog 64 EGFr humanized monoclonal antibody 64 arthritis PsA 64 erlotinib Tarceva R 64 Peginterferon alfa 2b 64 candidates Azedra TM 64 leukemia CLL 64 cisplatin gemcitabine 64 Bayer HealthCare Onyx Pharmaceuticals 64 recurrent metastatic ovarian cancer 64 Gemzar ® 64 radiation chemoradiation 64 carcinoma mCRC 64 accumulate preferentially 64 demonstrated antitumor activity 64 advanced metastatic renal 64 Vidaza ® 64 Relapsed Refractory 64 Cutaneous T 64 systemic anaplastic large 64 intravesical infusion therapy 64 relapsed leukemia 64 LHRH receptor positive 64 vinca alkaloids 64 substantially excreted 64 chemotherapy cisplatin 64 nilotinib Tasigna ® 64 ® lenalidomide 64 Ribavirin causes 64 docetaxel Taxotere R 64 EOquin TM phase 64 CTAP# Capsules 64 relapsing remitting MS RRMS 64 registrational Phase 63 Mg Usa 63 Refractory Hodgkin Lymphoma 63 5 fluorouracil leucovorin 63 PNP inhibitor 63 metastatic GIST 63 TRIOLEX HE# APOPTONE HE# 63 metastatic renal 63 situ CIS 63 BRIM2 63 Cariprazine 63 cutaneous T 63 novel emulsion formulation 63 vinorelbine tartrate 63 treatment naïve genotype 63 gemcitabine carboplatin 63 alfa 2a 63 naive HCV 63 evaluating T DM1 63 formerly LymphoStat B 63 unresectable stage 63 HCV NS5B polymerase 63 Xeloda ® 63 TO AVOID PREGNANCY WHILE 63 induced tumor regression 63 Bezielle 63 EGFr expressing metastatic colorectal 63 relapsed multiple myeloma 63 metastatic renal cell carcinoma 63 virus HCV protease inhibitor 63 oral proteasome inhibitor 63 pegylated liposomal doxorubicin 63 tumors GIST 63 telaprevir dosed 63 refractory metastatic 63 sapacitabine CYC# 63 unique alkylating agent 63 leukemia AML 63 aplastic anemia AA 63 recurrent glioblastoma multiforme 63 metastatic hormone refractory 63 Antitumor Activity 63 intravesical instillation 63 galiximab 63 cetuximab Erbitux R 62 systemic juvenile idiopathic 62 clinical trials Archexin 62 dacarbazine DTIC 62 Epothilone D 62 ® bortezomib 62 Elotuzumab 62 either acutely decompensated 62 CIMZIA ™ 62 low dose cytarabine 62 anti PlGF 62 alpha folate receptor 62 relapsing multiple sclerosis 62 refractory indolent non 62 hypereosinophilic syndrome 62 R Saizen R 62 Complicated Skin 62 AAG geldanamycin analog 62 R rilonacept Injection 62 ara C 62 delivers fluocinolone acetonide FA 62 leukemia multiple myeloma 62 MKC# MT 62 5 FU leucovorin 62 weekly subcutaneous injections 62 myelodysplastic myeloproliferative diseases 62 rheumatoid arthritis RA psoriatic 62 R lenalidomide 62 pancreatic prostate 62 sorafenib Nexavar ® 62 naïve HCV 62 adriamycin 62 imatinib resistant 62 Meets Primary Endpoint 62 patients receiving myelosuppressive 62 paclitaxel poliglumex 62 Ovitrelle R Serostim 62 refractory multiple myeloma 62 Wafer polifeprosan 62 Ibritumomab Tiuxetan 62 SPRYCEL ® 62 bevacizumab Avastin R 62 INSPIRE Trial Phase III 62 Xanafide 62 metaglidasen 62 pyrexia mucositis sepsis febrile 62 pediatric malignancies 62 Albuferon TM 62 monoclonal antibody IgG1 Mab 62 Syndrome LEMS 62 cyclophosphamide chemotherapy 62 VEGFR2 inhibitor 62 COPEGUS R 62 Ph + acute lymphoblastic 62 oral chemotherapeutic agent 62 Voreloxin 62 pan HDAC inhibitor 62 MabCampath 62 endocrine therapies 62 doxorubicin HCl liposome injection 62 vapreotide acetate 62 Paraplatin ® 62 neutropenia dehydration dyspnea 62 Aplidin 62 IMiDs ® compound 62 cutaneous T cell 62 PEGylated anti 62 intravenous belinostat 62 Vandetanib 62 complement inhibitor eculizumab 62 Tibotec Therapeutics division 62 Irinotecan 62 hormone refractory metastatic prostate 62 familial amyloidotic polyneuropathy FAP 62 Fludara ® 62 metastatic HER2 negative 62 Amigal TM 62 Diabetic Macular Edema 62 oral picoplatin 61 PegIFN 61 HER2 positive metastatic breast 61 AAG KOS 61 metastatic pancreatic 61 evaluating picoplatin 61 metastatic castration resistant 61 oral clodronate 61 TNF Tumor Necrosis Factor 61 metastatic neuroendocrine tumors 61 Peg IFN 61 bendamustine ifosfamide 61 essential thrombocythemia ET 61 Dacetuzumab 61 Ceplene/IL-2 61 Tarceva TM 61 non metastatic osteosarcoma 61 Lambert Eaton Myasthenic 61 evaluating tivozanib 61 oncolytic virus therapies 61 cisplatin resistant 61 recurrent metastatic 61 PrevOnco ™ 61 comparator arm 61 androgen independent 61 Zorbtive TM 61 Combination REOLYSIN R 61 FOLFOX6 chemotherapy regimen 61 pentadentate logo R 61 Fludarabine 61 gefitinib Iressa 61 Leukemias 61 receptor tyrosine kinase inhibitor 61 MT# MEDI 61 rALLy clinical trial 61 ACTEMRA TM 61 treatment naive genotype 61 DOXIL R 61 plus prednisone 61 Aflibercept 61 cytokine refractory 61 AKT inhibitor 61 Pemetrexed 61 LymphoStat B belimumab 61 CYP#A# CYP#D# 61 unresectable 61 remission induction 61 pan histone deacetylase 61 Nexavar ® 61 oropharyngeal candidiasis OPC 61 progressive metastatic prostate 61 PI3K/Akt pathway inhibitor 61 Neulasta R 61 YONDELIS 61 atypical Hemolytic Uremic Syndrome 61 EGFR expressing metastatic colorectal 61 MAGE A3 ASCI 61 mRCC 61 Umbilical cord stem cells 61 MET amplification 61 cisplatin chemotherapy 61 Fludara 61 anti EGFR antibody 61 recombinant PSMA vaccine 61 cell carcinoma RCC 61 bortezomib Velcade R 61 KRAS wild 61 docetaxel Taxotere ® 61 ankylosing spondylitis psoriatic arthritis 61 completely resected 61 Alseres Cethrin 61 castrate resistant prostate cancer 61 Dementia Related Psychosis 61 GTC recombinant human 61 peritoneal carcinomatosis 61 vascular occlusive diseases 61 metastatic colorectal 61 Systemic lupus erythematosus SLE 61 CTA# Injection 61 fluoropyrimidine 61 orally administered inhibitor 61 locoregional 61 CTAP# 61 Hormone Refractory Prostate Cancer 61 fallopian tube carcinoma 61 sunitinib malate 61 Peginterferon 61 taxane resistant 61 decompensated liver disease 61 Etanercept 61 IMiDs ® 61 CHOP chemotherapy 61 Soft Tissue Sarcoma 61 oral prodrug 61 Copegus R 61 unresectable Stage III 61 Cell Non Hodgkin 61 acyclovir Lauriad R 61 stage IIIb 61 Congenital Emphysema 61 plus DOXIL 61 somatostatin analog 61 evaluating Vectibix 61 small lymphocytic lymphoma 61 DOXIL 61 Advanced Renal Cell 61 HGS ETR2 61 smoldering multiple myeloma 61 imatinib Gleevec ® 61 chronic myeloid 61 Philadelphia Chromosome Positive 61 OMNARIS HFA 61 Annamycin 61 K ras mutations 61 epithelial tumors 61 hyperphenylalaninemia HPA due 61 IAP inhibitor 61 Folfox 61 Omacetaxine 61 CD4 monoclonal antibody 61 RhuDex R 61 Temsirolimus 61 Naive Patients 61 cell acute lymphoblastic 60 Daclizumab 60 FOLFIRI alone 60 novel topoisomerase 60 Glioblastoma multiforme GBM 60 BRAF V#E 60 refractory acute myeloid 60 combining voreloxin 60 brand ciclesonide HFA 60 acute myeloid 60 basal cell carcinoma BCC 60 ceroid lipofuscinosis NCL 60 liposomal amphotericin B 60 doxorubicin Adriamycin 60 papillary renal cell carcinoma 60 lenalidomide Revlimid ® 60 prostate cancer HRPC 60 induced macular edema 60 Oral NKTR 60 myocardial infarction ventricular fibrillation 60 autoantibody positive 60 Navelbine ® 60 HuMax EGFr 60 prokinetic agent 60 anthracycline taxane 60 untreated metastatic melanoma 60 small molecule Hedgehog 60 AML MDS 60 osteosarcomas 60 targeted radiotherapeutic 60 Solazed TM 60 recurrent glioblastoma 60 developing Bicifadine serotonin 60 mg q#h 60 topical gel formulation 60 castration resistant hormone refractory 60 sunitinib Sutent ® 60 Mg Uk 60 metastatic RCC 60 haematologic 60 plus gemcitabine 60 Camptosar ® 60 opioid naive 60 oral rivaroxaban 60 Chronic lymphocytic leukemia 60 bone marrow lymph nodes 60 Romidepsin 60 alpha interferons 60 trabectedin 60 TNF alpha selectively neutralizing 60 Letairis ambrisentan 60 OncoVEX GM CSF 60 systemic ALCL 60 toenail onychomycosis 60 pharmacologically active isomer 60 unresectable liver cancer 60 included exfoliative dermatitis 60 receiving chemoradiation therapy 60 EGFR mutation positive 60 diagnosed glioblastoma multiforme 60 prostate carcinoma 60 anaplastic astrocytoma AA 60 CML CP 60 ceftazidime 60 Cardium Therapeutics TM 60 proteasome inhibitor 60 refractory Ph + 60 diagnosed Ph + 60 HYVISC ® treatment 60 bendamustine 60 anthracycline containing 60 lymphoma CTCL 60 Frozen Shoulder syndrome Adhesive 60 PLX STROKE targeting 60 lung pancreatic 60 B CLL 60 syngeneic 60 xenograft models 60 palonosetron hydrochloride Injection Dacogen 60 MKC# MKC# PP 60 metastatic androgen independent 60 potentially hepatotoxic 60 huN# DM1 60 vinca alkaloid 60 Patients Treated With 60 leukemia APL 60 oral ridaforolimus 60 MKC# 60 pegylated interferon alfa 2a 60 oral dihydropyrimidine dehydrogenase DPD 60 irinotecan containing 60 glioblastoma multiforme GBM 60 Stereotactic body 60 gastrointestinal disorders characterized 60 NS5B polymerase 60 interferon alpha IFN alpha 60 relapsed myeloma 60 sorafenib Nexavar R 60 vinorelbine 60 potent topoisomerase II 60 Peginterferon Alfa 2a 60 pathophysiological effects 60 Amrubicin 60 evaluating carfilzomib 60 personalized cellular immunotherapy 60 CALGB # [002] 60 superficial basal cell carcinoma 60 omega interferon 60 FEMALES SHOULD BE ADVISED 60 metastatic malignant melanoma 60 PRTX 60 oral nucleoside analogue 60 Acute myeloid leukemia 60 iobenguane 60 potent triglyceride lowering 60 advanced hepatocellular carcinoma 60 mertansine 60 metastatic colorectal carcinoma 60 serologically active systemic lupus 60 epithelial ovarian 60 Levoleucovorin 60 5 Fluorouracil 60 Phase #/#a trial 60 antibody MAb 60 ENMD # 60 tyrosine kinase inhibitor TKI 60 Refractory Peripheral T 60 refractory colorectal cancer 60 FOLFOX6 60 PEGylated interferon beta 1a 60 MGd 60 cirrhotic CHC monoinfected patients 60 previously untreated follicular 60 myeloproliferative neoplasms MPNs 60 plus COPEGUS 60 tenofovir disoproxil fumarate Viread 60 AEG# 60 virus HCV infection 60 OncoVex 60 taxane chemotherapy administered 59 liposomal formulation 59 chronic ITP patients 59 ® adefovir dipivoxil 59 colon carcinoma 59 gemcitabine cisplatin 59 interferon gamma 1b 59 Follicular Lymphoma 59 palifermin 59 interferon alfa 2b 59 alvespimycin 59 visilizumab 59 advanced unresectable 59 IMiDs R 59 Campath alemtuzumab 59 Intravitreal injections 59 DURECT proprietary 59 multiple myeloma MM 59 FOLFIRI 59 evaluating REVLIMID 59 budesonide foam 59 thetreatment 59 underwent surgical resection 59 estramustine 59 hepatitis C HCV 59 VFEND 59 HBeAg negative 59 D aspartate NMDA receptor 59 acetonide FA 59 pancreatic adenocarcinoma 59 ug dose 59 Methylnaltrexone 59 relapsed SCLC 59 PEGINTRON TM 59 Veronate R 59 sorafenib Nexavar 59 Lenalidomide 59 vaginal candidiasis 59 refractory AML 59 Randomized Phase 59 Second Pivotal Phase 59 Palifosfamide 59 fusion enhancers 59 reduce serum phosphate 59 Bosutinib 59 IMiDs 59 induced mucositis 59 CYP#A# substrate 59 KRAS mutant 59 follicular Non Hodgkin 59 Aplidin R 59 metastatic malignant 59 ALN HPN 59 overactive bladder AA# 59 follicular lymphomas 59 mitoxantrone plus 59 HCl PEPCID ® famotidine 59 deCODE ProstateCancer TM 59 refractory cutaneous T 59 PEGylated Fab fragment 59 FOLFOX chemotherapy 59 EGFR expressing mCRC 59 TNF blocker therapy 59 saline placebo 59 EQUIP OB 59 8mg/kg 59 GI GVHD common 59 selective modulator 59 chronic HCV genotype 59 chronic eosinophilic leukemia 59 polyneuropathy HIV DSP 59 Panzem R NCD 59 Adjuvant chemotherapy 59 acute myelogenous 59 Hepatocellular Carcinoma HCC 59 postoperative chemotherapy 59 acute promyelocytic leukemia APL 59 Seliciclib 59 Acute Myeloid Leukemia AML 59 nucleoside naive 59 cyclophosphamide doxorubicin vincristine 59 gastrointestinal stromal tumor GIST 59 catheter occlusion 59 rheumatoid arthritis psoriatic arthritis 59 hepatocellular liver 59 HER2 overexpression 59 TEMODAL 59 MYDICAR ® 59 oral antidiabetic medication 59 carboplatin paclitaxel 59 constipation OIC 59 peptidic compound 59 mCRC patients 59 Metastatic Colorectal Cancer 59 placebo dexamethasone 59 Paroxysmal Nocturnal Hemoglobinuria PNH 59 PKC# 59 refractory NSCLC 59 unresectable locally advanced 59 daunorubicin 59 novel synthetic PEGylated 59 receiving immunosuppressive therapy 59 carcinoma HCC 59 COPEGUS ribavirin 59 Acute Myelogenous Leukemia AML 59 medically inoperable 59 oral FTY# 59 Lymphocytic 59 PROSTVAC VF 59 biliary tract cancer 59 liposomal doxorubicin 59 receiving XGEVA 59 NMIBC 59 standard chemotherapy regimen 59 retroperitoneal bleeding 59 thalidomide Thalomid 59 Arsenic trioxide 59 Taxotere ® 59 Pegasys ® 59 INTEGRILIN R 59 mcg albinterferon alfa 2b 59 relapsed Acute Myeloid 59 CIMZIA TM 59 neutropenia thrombocytopenia 59 Kinesin Spindle Protein KSP 59 Gliadel Wafer 59 Platinol ® cisplatin 59 Papillary 59 subependymal giant cell 59 ocular formulation 59 non resectable metastatic 59 Doxil ® 59 world safest multivalent 59 Gleevec resistant 59 Taxol ® 59 recurrent malignant glioma 59 infectious diseases autoimmune diseases 59 GVAX Pancreas Vaccine 59 PEG interferon 59 gemcitabine Gemzar ® 59 squamous cell carcinoma SCC 59 Copegus ® 59 Degarelix 59 evaluating Prochymal 59 anthracyclines taxanes 59 non nucleoside inhibitor 59 Diffuse Large B 59 IgG1 monoclonal antibody 59 HER2 positivity 59 soft tissue sarcomas 59 KRAS mutations occur 59 gastrointestinal stromal tumor 59 Epratuzumab 59 Nilotinib 59 5-FU/LV 59 evaluating mipomersen 59 methylnaltrexone bromide 59 Entereg R 59 metastatic gastric 59 sapropterin dihydrochloride Tablets 59 #-# rDNA origin 59 successfully commercialize Iluvien 59 BR.# 59 TELCYTA 59 forodesine 59 Vidofludimus 59 Luveris R Ovidrel R 59 sarcomatoid 58 Adecatumumab 58 DexaSite 58 gemcitabine chemotherapy 58 PROCHYMAL 58 XL# XL# 58 relapsed acute myelogenous 58 Trastuzumab DM1 58 ovarian endometrial 58 poly ADP ribose polymerase 58 refractory chronic myeloid 58 romidepsin 58 headache nasopharyngitis 58 paclitaxel Taxol ® 58 dacarbazine 58 Atypical Hemolytic Uremic Syndrome 58 radiolabeled TM# 58 Trial Evaluating 58 TMC# C# 58 Castration Resistant Prostate Cancer 58 histologically confirmed 58 temsirolimus 58 Ozarelix 58 DEB# 58 castration resistant prostate cancer 58 PD LID 58 systemically administered 58 ALN TTR# 58 neuroendocrine cancers 58 Genasense ® 58 XYOTAX TM 58 ErbB2 positive 58 Stage IIIb 58 histone deacetylase inhibitor 58 Bendamustine 58 AVONEX ® 58 adrenocortical cancer 58 EDEMA3 58 Thiarabine 58 IV metastatic melanoma 58 Brentuximab Vedotin SGN 58 infusional 5-FU/LV 58 asymptomatic metastatic 58 non resectable 58 deep venous thromboses 58 THAT ARE DIFFICULT TO 58 radiotherapy RT 58 basal cell carcinoma squamous 58 cell chronic lymphocytic 58 lymphomas leukemias 58 anastrazole 58 Smac mimetic 58 AVASTIN 58 diarrhea predominant irritable 58 pegylated interferon peg IFN 58 pegylated interferon alpha 2a 58 unresectable recurrent 58 Inhaled nitric oxide 58 Relapsed Refractory Multiple Myeloma 58 cytarabine daunorubicin 58 4mg/kg 58 Xcellerated T Cells 58 skeletal metastases 58 class mGluR5 inhibitor 58 Panzem NCD 58 Crohn disease CD 58 Clolar ® 58 locoregional recurrence 58 concurrent chemoradiation 58 PDX pralatrexate 58 EGFr expressing mCRC 58 Initiates Phase II 58 Ceflatonin R 58 achieved ACR# 58 gastrointestinal stromal tumors 58 castrate resistant 58 sunitinib Sutent 58 achieved CCyR 58 Newly Diagnosed Multiple Myeloma 58 Pegylated Interferon 58 metastatic HRPC 58 Safinamide 58 lexidronam injection 58 investigational monoclonal antibody 58 neovascular diseases 58 Flu Cy 58 T1c 58 pain palliation 58 zoledronate 58 6 mercaptopurine 58 Triapine R 58 doxorubicin cyclophosphamide 58 SUPPRELIN R LA 58 calcineurin inhibitor 58 Xelox 58 ovarian bladder 58 cancer mCRC 58 mg/m2 administered 58 chlorambucil 58 ALN TTR 58 interferon alfa 58 QUADRAMET R 58 idarubicin 58 Vincristine 58 Retisert R 58 pancreatic colon 58 OPAXIO 58 use transdermal sumatriptan 58 TRIOLEX ™ 58 Myelofibrosis 58 antiangiogenic therapy 58 Pruvel ™ prulifloxacin 58 Evoltra ® 58 ELACYT 58 Phase 2b Clinical Trial 58 HuCAL PLATINUM ® CysDisplay 58 Darinaparsin 58 Cannabinor 58 PREZISTA r 58 primary immunodeficiency PI 58 fludarabine 58 protein kinase inhibitor 58 interferon alfa 2a 58 cervical carcinoma 58 PROCRIT ® 58 alkylating agents 58 Telatinib 58 resistant hormone refractory 58 BENLYSTA ® 58 SIR Spheres 58 Angiotensin receptor blockers 58 unresectable HCC 58 R bisoprolol Euthyrox 58 Genasense R 58 follicular lymphoma FL 58 Nexavar sorafenib 58 PSMA ADC 58 metastatic castrate resistant 58 pralatrexate injection folate analogue 58 oral levofloxacin 58 myelofibrosis MF 58 pancreatic islet beta 58 huC# DM4 58 Pralatrexate 58 hereditary deficiency 58 Metastatic Renal Cell Carcinoma 58 untreated metastatic colorectal 58 thymalfasin 58 lintuzumab SGN 58 Chronic Hepatitis C 58 Pivotal Phase III 58 fluoroquinolone class 58 Cloretazine 58 splenectomized 58 IV NSCLC 58 Phase #b/#a clinical 58 Traficet EN 58 CR nPR 58 Tipranavir 58 pheochromocytoma 58 primary humoral immunodeficiency 58 Chronic lymphocytic leukemia CLL 58 fallopian tube cancers 58 oral rehydration IV 58 mapatumumab 58 riociguat 58 Edge STudy 58 Advanced Melanoma 58 Decitabine 58 Fingolimod 58 Carcinoid tumors 58 folinic acid 58 primary hypercholesterolemia 58 CysDisplay R 58 lymphoid cancers 58 oligodendrogliomas 58 tiuxetan 58 Cojocaru correspondent 58 Granulocyte Colony Stimulating Factor 58 Capecitabine 58 Lupus nephritis 58 aflibercept VEGF Trap 58 Phase IIb Trial 58 steroid refractory ulcerative 58 tumor lysis syndrome 58 FOLFOX 58 R vitespen 58 5 lipoxygenase inhibitor 58 chronic lymphocytic 58 Fovea Pharmaceuticals subsidiary 58 Proxinium TM 58 FOLFOX4 58 Metastatic Melanoma 58 mycosis fungoides 58 Aeroquin 58 Pharmacokinetics PK 58 cell lymphoma CTCL 58 orally bioavailable 58 Investigational Treatment 58 rALLy 58 leukemia lymphoma multiple myeloma 58 underwent resection 58 ZACTIMA TM ZD# 58 tuberous sclerosis TS 58 Zenvia ™ 58 histone deacetylase HDAC inhibitor 58 mildly symptomatic 58 interleukin IL -# 58 exocrine pancreatic insufficiency EPI 58 ribavirin RBV 58 EGFR TKI 58 acetylgalactosamine 6 58 HQK 58 bevacizumab Avastin ® 58 EndoTAGTM 1 58 peginterferon alfa 58 commercialize deforolimus 58 Initiate Phase 58 CCR9 antagonist 58 relapsed mantle 58 Panzem R 58 gemcitabine Gemzar 58 Warner Chilcott Actonel 58 Solazed ™ 58 Completes Patient Enrollment 58 NR2B selective 58 VELCADE melphalan 58 Racivir 58 HGS ETR1 58 hypertrichosis occurred 58 paclitaxel cisplatin 58 advanced pancreatic neuroendocrine 58 pegylated interferon alfa 2b 58 bleomycin 58 Generx TM 58 TELINTRA 57 mitomycin C 57 immunotherapeutic agent 57 Vitrasert R 57 raloxifene Evista 57 GW# [003] 57 Glioblastoma Multiforme 57 CINQUIL 57 anti angiogenic agents 57 doublet chemotherapy 57 hepatocellular carcinoma HCC 57 Hodgkin lymphoma NHL 57 Imatinib mesylate 57 metastatic relapsed 57 leukemia myeloma 57 docetaxel Taxotere 57 cleavable linker 57 HCV SPRINT 57 Allovectin 7 ® 57 metastatic renal cell 57 Waldenstrom macroglobulinemia 57 Nexavar sorafenib tablets 57 DAVANAT 57 HIV coinfected 57 receiving VELCADE 57 Pegylated interferon 57 Initiates Enrollment 57 RESTORE CLI trial 57 UPLYSO 57 CIMZIA TM certolizumab pegol 57 Herceptin trastuzumab 57 myelofibrosis polycythemia vera 57 superficial bladder cancer 57 NOTE POSIDUR ™ 57 colorectal adenocarcinoma 57 Neovascular AMD 57 diagnosed GBM 57 Alemtuzumab 57 esophageal candidiasis 57 non splenectomized 57 lenalidomide dexamethasone 57 humanised monoclonal antibody 57 metastatic bladder 57 indolent NHL 57 TORISEL 57 cetuximab Erbitux ® 57 paclitaxel Taxol R 57 systemic sclerosis SSc 57 AzaSite ISV 57 Dupuytren Disease 57 malignant ovarian 57 cyclophosphamide methotrexate 57 RhuDex TM 57 receiving TNF blockers 57 receiving highly emetogenic 57 MYLOTARG 57 Mantle Cell Lymphoma 57 SCCHN 57 multicenter Phase III 57 Myelodysplastic Syndrome 57 selective kinase inhibitor 57 TYKERB 57 hormone receptor negative 57 ACTIQ ® 57 ER CHOP 57 chimeric monoclonal antibody 57 EGFR tyrosine kinase inhibitor 57 non mutated KRAS 57 FluCAM 57 imatinib Gleevec 57 Heterozygous Familial Hypercholesterolemia 57 Bacille Calmette Guérin BCG 57 favorable pharmacokinetic profile 57 TRAIL induced apoptosis 57 Tofacitinib 57 daily injectable lipoglycopeptide 57 Serostim ® 57 CTEPH 57 breast carcinomas 57 R MSCRAMM 57 trastuzumab DM1 T DM1 57 untreated chronic lymphocytic 57 EGFR HER2 57 Bavituximab 57 CD# expressing 57 refractory prostate cancer 57 Junovan 57 mCRC acneform rash 57 dextromethorphan quinidine 57 potent antiproliferative 57 PRN FDA Approves 57 chronic lymphocytic leukemia CLL 57 neoadjuvant 57 membranous nephritis 57 nilotinib 57 aldehyde dehydrogenase ALDH2 deficiency 57 Cytoxan 57 tigecycline 57 corticosteroid dexamethasone 57 TRAIL R1 57 factor alpha TNF 57 ANCA associated 57 castration resistant 57 Epstein Barr Virus EBV 57 Anthracycline 57 TM pralatrexate injection 57 molecular chaperone regulator 57 assessing T DM1 57 hormone LHRH antagonist 57 Temodar ® 57 paroxysmal nocturnal hemoglobinuria PNH 57 refractory Hodgkin 57 Alocrest 57 heavily pretreated 57 Obatoclax 57 arsenic trioxide injection 57 Abiraterone Acetate 57 Sapacitabine 57 mocetinostat MGCD# 57 malignant ascites 57 cisplatin carboplatin 57 markets Testim ® 57 DMARDS 57 diagnosed chronic myeloid 57 Hodgkin lymphoma HL 57 allogeneic bone marrow 57 steroid refractory 57 NUVIGIL ® 57 certolizumab 57 ADVEXIN therapy 57 dilated cardiomyopathy DCM 57 Thalomid ® 57 Trastuzumab 57 anthracycline chemotherapy 57 LEUKINE 57 taxane refractory 57 Tiuxetan 57 label Lipofen R 57 dose melphalan 57 PREZISTA rtv 57 SinuNase TM 57 papillary thyroid carcinoma